OPKO Health Inc at JPMorgan Healthcare Conference Transcript
Good morning, everyone. I'm Steve Rubin. I'm the Executive Vice President of OPKO Health, and I will be presenting the first half of this deck; and Jon Cohen, who is the Executive Chair of our Laboratory and Diagnostics business, will be presenting the second half. Thank you all for coming. Forward-looking statements, if you'd like to read them.
So OPKO is diversified across several business assets, makes us a little bit unique. So we have marketed pharmaceuticals, leading off with RAYALDEE that we have launched in 2016. It addresses an unmet need in the chronic kidney disease market. Revenue in the third quarter was about $7.4 million. As I will cover later, it's been growing fairly significantly of late, which we're pleased to see after a relatively slow start. It's partnered with Vifor Fresenius outside the U.S. and is partnered with JT-Torii or Japan Tobacco in Japan.
As the pipeline, I'll talk a lot about one of the most exciting ones. We announced positive data on our Long-acting Human Growth
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
